Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

NCT00943293 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Poor accrual; did not enter phase 2

Conditions

Preleukemia
Myeloproliferative Disorders
Lymphoma
Myeloma
Graft Versus Host Disease

Interventions

DRUG: Fludarabine
DRUG: Melphalan
DRUG: Campath

Sponsor

University of Chicago